|
EP3722285A1
|
|
Process for preparing mirabegron enacarbil
|
|
EP3744320A1
|
|
Pharmaceutical tablet composition comprising edoxaban
|
|
EP3756653A1
|
|
Microparticulate varenicline citrate
|
|
EP3696169A1
|
|
Manufacturing process for amifampridine phosphate
|
|
EP3641735A1
|
|
Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
|
|
EP3511001A1
|
|
Pirfenidone-containing tablet and capsule formulation
|
|
WO2019073062A1
|
|
Tablet containing valsartan and sacubitril
|
|
EP3409272A1
|
|
Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
|
|
US2021085610A1
|
|
Stable hot-melt extrudate containing valsartan and sacubitril
|
|
WO2018178295A1
|
|
Stable hot-melt extrudate containing valsartan and sacubitril
|
|
EP3354283A2
|
|
Pharmaceutical capsule composition comprising silodosin
|
|
EP3501506A1
|
|
Pharmaceutical tablet composition comprising brexpiprazole
|
|
EP3470062A1
|
|
Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
|
|
EP3453384A1
|
|
Pharmaceutical tablet composition comprising bilastine
|
|
EP3395331A1
|
|
Pharmaceutical tablet composition comprising eltrombopag olamine
|
|
EP3412656A1
|
|
Crystalline forms of amifampridine dihydrochloride
|
|
EP3360866A1
|
|
Mirabegron prodrugs
|
|
EP3284499A1
|
|
Dry powder inhaler with reproducible flow resistance
|
|
EP3590505A1
|
|
Gastro-resistant formulation containing posaconazole
|
|
EP3175842A1
|
|
Dry powder mixing process
|
